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Using the contribution matrix 
to evaluate complex study limitations in a 
network meta-analysis: a case study of bipolar 
maintenance pharmacotherapy review
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Abstract 
Background: Limitations in the primary studies constitute one important factor to be considered in the grading of 
recommendations assessment, development, and evaluation (GRADE) system of rating quality of evidence. How-
ever, in the network meta-analysis (NMA), such evaluation poses a special challenge because each network estimate 
receives different amounts of contributions from various studies via direct as well as indirect routes and because some 
biases have directions whose repercussion in the network can be complicated.
Findings: In this report we use the NMA of maintenance pharmacotherapy of bipolar disorder (17 interventions, 
33 studies) and demonstrate how to quantitatively evaluate the impact of study limitations using netweight, a STATA 
command for NMA. For each network estimate, the percentage of contributions from direct comparisons at high, 
moderate or low risk of bias were quantified, respectively. This method has proven flexible enough to accommodate 
complex biases with direction, such as the one due to the enrichment design seen in some trials of bipolar mainte-
nance pharmacotherapy.
Conclusions: Using netweight, therefore, we can evaluate in a transparent and quantitative manner how study limita-
tions of individual studies in the NMA impact on the quality of evidence of each network estimate, even when such 
limitations have clear directions.
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Background
The number of network meta-analyses (NMA) has been 
increasing rapidly in recent years [1], and concomitantly 
the methodology for NMA is also quickly developing and 
expanding. One of the most important topics around 
NMA currently is how we should assess the quality of 
evidence provided by NMA. Two papers have been pub-
lished recently that attempt to apply the grading of rec-
ommendations assessment, development, and evaluation 
(GRADE) system of rating quality of evidence to NMA 
[2, 3].
According to GRADE, various components impact on 
the quality of findings from systematic reviews. Limita-
tions in the primary studies constitute one important fac-
tor that can influence the quality of the pooled estimates. 
In traditional pairwise meta-analyses, the evaluation of 
study limitations of the included studies is fairly straight-
forward because one can visualise each study’s risks of 
bias in a table format and then evaluate their contribu-
tions to the pairwise meta-analytic results directly. On 
the other hand, NMA poses a special challenge in this 
assessment because different NMA estimates receive dif-
ferent amounts of contributions from all the studies in 
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the network via direct as well as indirect contributions, 
and their respective contributions are not apparent.
The method proposed by Puhan et  al. [2] rates the 
quality of evidence separately for direct and indirect 
estimates, and each rating is more impressionistic than 
quantitative. Moreover, when the network has many 
nodes and is more complex than triangular, they rec-
ommend focusing on the so-called first order loop (i.e. 
the triangular loop) for examination of the indirect esti-
mates and suggests using the higher of the two ratings as 
the rating of the network estimate. In other words this 
method fails to take into account the remaining contri-
butions. The authors therefore calls for research in how 
to use weights of individual studies in evaluating quality 
of NMA estimates [2]. The method proposed by Salanti 
et al. [3] uses weights more extensively and makes more 
quantitative evaluations of all the involved evidence. We 
applied this method in a previous NMA on maintenance 
pharmacotherapy of bipolar disorder [4], while paying 
due attention to the amount of contribution from each 
individual study.
The problem of “enrichment design” in bipolar 
maintenance pharmacotherapy studies
The appraisal of the impact of study limitations in the 
NMA of the maintenance pharmacotherapy of bipolar 
disorder presents an additional interesting feature that 
renders this assessment even more challenging.
Bipolar disorder is a psychiatric disease in which 
patients typically show recurrent episodes of both manic 
and depressive episodes. While acute treatment is aimed 
at treating the acutely manic or depressive symptoms, 
long-term maintenance treatment is usually neces-
sary to minimise the risk of recurrence of both manic 
and depressive episodes. Bipolar patients recruited into 
maintenance or prophylactic studies are usually in an 
euthymic phase, without acute symptoms. In some of 
these clinical trials, however, only the participants who 
had achieved remission of the index acute manic or 
depressive episode by treatment with a certain drug were 
included in the maintenance phase of the trial and then 
were randomised to continue the same drug or switch to 
another active drug (or placebo). Such a study design is 
called ‘enrichment design’, as it is ‘enriched’ by patients 
whose acute manic or depressive episode had responded 
to the drug used in the acute phase.
This study design has many limitations [5]. In particu-
lar, its results will tend to favour the drug that was effec-
tive in the acute phase mainly in the prevention of future 
episodes of the same polarity as the index episode and 
not necessarily in the prevention of episodes of the oppo-
site polarity. The risk of bias due to the enrichment design 
therefore has a direction. For example, if a study included 
only those who had remitted from a manic episode on 
drug X and randomised them to continue on drug X or 
to switch to drug Y in order to compare these interven-
tions’ efficacy in preventing a new manic or depressive 
episode, it is easy to foresee that such patients’ future 
manic episodes would be relatively responsive to drug X 
but possibly not their depressive episodes. On the other 
hand, drug Y is clearly not favoured in any direction as 
the patients had been originally selected as responders to 
drug X.
In the present article we use a published NMA as a 
working example and present a transparent and system-
atic method to assess how study limitations of individual 
randomised controlled trials (RCTs), including those due 
to the enrichment design, impact on the quality of evi-
dence in the NMA. In NMA, it is almost certain that 
confidence in estimates will vary from comparison to 
comparison. We therefore essayed to appraise the qual-
ity of evidence for each comparison contained in the 
network. In the following we will illustrate how study 
limitations without direction (i.e. risks of bias usually 
assessed according to the Cochrane Handbook) and then 
those with direction (i.e. risk of bias due to the enrich-
ment design) can be quantitatively summarised and eval-
uated to characterise each network estimate.
Methods
Materials
The NMA in question represents a systematic review of 
randomised controlled trials that compared active treat-
ments for bipolar disorder (or placebo), either as mono-
therapy or as add-on treatment, for at least 12 weeks [4]. 
The primary outcome was the number of participants 
with recurrence of any mood episode this primary out-
come was a combination of two secondary outcomes, 
namely the number of participants with recurrence of 
a manic episode and those with recurrence of a depres-
sive episode. All in all we identified and included 33 
randomised controlled trials that examined 17 mainte-
nance pharmacotherapies for bipolar disorder in 6846 
participants. Figure 1 shows the network formed by the 
identified comparisons in this NMA. We conducted a 
random-effects network meta-analysis within a Bayesian 
framework using Markov chain Monte Carlo in Open-
BUGS 3.2.2. [6].
Assessment of risk of bias of each study and of each direct 
comparison
Two assessors rated the risk of bias (RoB) of each RCT 
according to the Cochrane Handbook risk of bias 
tool [7]. The RoB examines the key methodological 
issues in a randomised trial, such as generation of ran-
dom sequence, concealment of allocation, blinding of 
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participants, blinding of therapists, blinding of outcome 
assessment, incomplete outcome data, and selective out-
come reporting. We also assessed whether the definitions 
of the mood episode relapse or recurrence were explicit/
operationalised or not in the primary studies, and the 
sponsorship bias. We rated an item at unclear risk of bias 
when we did not find sufficient information to judge it at 
either high or low risk.
Then we made a summary evaluation of RoB for each 
included study according to the following categories:
Low risk of bias: there is no item rated at high risk 
among the nine items listed above.
Moderate risk of bias: there is one item rated at high 
risk.
High risk of bias: there are two or more items rated at 
high risk.
We examined the validity of this classification by pool-
ing and comparing RR for studies rated as low, moder-
ate or high risk of bias in a comparison if this comparison 
had an enough number of included trials to enable such 
validation.
After making a summary evaluation of RoB for each 
study, we made a similar evaluation of RoB for each 
direct comparison. When studies rated at different risks 
of bias were pooled, we made a summary evaluation by 
taking into account the weight that each study is given in 
pooling the studies into one direct comparison estimate 
as follows:
Low risk of bias: all the included studies were rated as 
low risk of bias.
Moderate risk of bias: all the studies were rated as 
moderate or low risk of bias; or there was one study 
rated as high risk of bias but this study contributed 
less than one quarter of the pooled sample.
High risk of bias: there are two or more studies rated at 
high risk; or one major study at high risk of bias made a 
substantial contribution.
The above method of summarising RoBs of various 
domains into RoB of a study and then summarising study 
RoBs into RoB of a comparison is admittedly to a certain 
extent arbitrary. However, it must be noted that we can 
use the same logic and calculations, as we demonstrate 
below, to synthesise these characteristics at the level of 
each pairwise comparison into those at the level of each 
network estimate. In the following we shall therefore use 
the definitions above to illustrate our method.
Assessment of ‘enrichment design’ for each study and for 
each direct comparison
We also evaluated whether each study used the enrich-
ment design in relation with the polarity of the mood 
episode. The influence of the enrichment design was 
assessed separately for the two secondary outcomes: pre-
vention of depressive episodes and prevention of manic 
episodes. Participants were considered to be enriched for 
a certain drug for depressive episode relapse (depressive 
enrichment) when they had been recruited at an acute 
depressive episode and investigated for the depressive 
episode relapse after being stabilised by that drug, and 
participants were considered to be enriched for a drug 
for manic episode relapse (manic enrichment) when they 
had been recruited at an acute manic episode and investi-
gated for the manic episode relapse after being stabilized 
by that drug.
We first calculated the percentages of both depres-
sive and manic enrichment for each study according to 
the number of participants in acute depressive or manic 
episode at recruitment, and then we estimated the cor-
responding percentages for each direct comparison con-
sisting of one or more studies with consideration of the 
direction of enrichment for each study. For example, if a 
direct comparison A vs B consisted of two studies, one of 
which (n = 100) did not use the enrichment design but 
the other (n = 200) recruited patients at their depressive 
Fig. 1 Network of eligible comparisons in the multiple-treatment 
meta-analysis for any mood episode relapse. Each node (circle) cor-
responds to a drug included in the analyses, with the size propor-
tional to the number of participants assigned to that drug. Each line 
represents different comparisons between drugs, with the width 
of the line proportional to the number of trials comparing each 
pair of treatments. ARP aripiprazole, CBZ carbamazepine, FLX fluox-
etine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, 
OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, 
RisLAI risperidone long-acting injection, VPA valproate
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episodes and treated them with drug A, then this direct 
comparison would have 67  % (200/300) of participants 
enriched for depressive relapse in favour of drug A, 
33 % not enriched for depressive relapse and 100 % not 
enriched for manic relapse.
Using the contribution matrix to quantify the influence 
of RoB and of enrichment design in each network estimate
We used a recently developed tool for NMA, called the 
contribution matrix, that quantifies how much each 
direct comparison in the network contributes to each 
network estimate in the NMA [8, 9].
Let’s take a simple, triangular network ABC. We first 
calculate the direct estimate comparing A vs B, A vs C 
and B vs C by pooling trials comparing A vs B, A vs C, 
and B vs C, respectively. We denote these as DAB, DAC and 
DBC. In the NMA of the full triangle, the mixed or net-
work estimate comparing A vs B comes from the direct 
comparison DAB and the indirect comparison IAB con-
sisting of DBC and DCA via C. For the simple situation in 
which each of the direct estimates has the same variance, 
the network estimate NAB is (2*DAB  +  (DAC−DBC))/3. 
Thus, for the mixed estimate (or also called network esti-
mate) NAB, the three direct estimates DAB, DAC and DBC 
makes contributions of 50, 25 and 25 %, respectively.
When the network structure is complex and when vari-
ances are not equal, calculating the contribution of each 
direct estimate to each network estimate in the NMA is 
more complicated. In general more weight is given to 
direct comparisons with more precision and to those that 
are more central to the network and thus contribute to 
more indirect comparisons. Using the netweight com-
mand in Stata [10], we calculated the contribution matrix 
showing contributions from each direct comparison to 
the network comparisons. The weight that each direct 
comparison contributes to the network estimates is a 
combination of the variance of the direct comparison and 
the network structure: a comparison with much direct 
information not only contributes much to the network 
estimate of that comparison but also is more influential 
on its neighboring comparisons than its remotely placed 
comparisons, and a comparison for which little direct 
evidence exists benefits most from the rest of the net-
work. Using netweight,1 the percentage contribution of 
each direct comparison to each network estimate is sum-
marised in a matrix with rows representing network esti-
mates and columns representing the available direct 
comparison in the network.
1 The STATA command will be in the form of netweight effect_size SE_of_
effect_size treatment1 treatment2    where each row in the dataset repre-
sents the effect size and its standard error for a study comparing treatment1 
and treatment2. For more details, please see [8] and [10].
In order to characterize the RoB of each network 
estimate, we multiplied the contributions from direct 
comparisons at low, moderate or high risk of bias, respec-
tively, by the contribution percentage that each direct 
estimate is making to the network estimate. This calcula-
tion provided the percentage of contributions from direct 
estimates rated at low, moderate or high risk of bias, 
respectively, to each network estimate.
In order to quantify the contribution from enrichment 
design to each network estimate, we multiplied the per-
centage of enrichment for each direct comparison by 
the contribution percentage that each direct estimate is 
making to the network estimate. For a particular network 
estimate of A vs B, this calculation provided the percent-
age of contributions from enriched studies favouring A, 
those favouring B, those dis-favouring A (i.e. favouring 
another drug C over A), those dis-favouring B, and those 
that involve neither A nor B (enrichment of unknown 
direction). The remaining came from non-enriched stud-
ies. We summed up the percentage of contributions from 
studies favouring A and those dis-favouring B as the per-
centage of enrichment favouring A. In the same manner, 
the percentage of enrichment favouring B was calculated 
by summing up the percentage of contributions from 
studies favouring B and those dis-favouring A.
Results
RoB of network estimates
Table 1 lists RoB for each individual study, and the sum-
mary assessment of RoB for each direct comparison, fol-
lowing the general rules as described in the methods. 
Placebo vs lithium was the only comparison where we 
had an enough number of trials at high, moderate or low 
risks of bias to compare the effect estimates for the same 
underlying true effect. Pooled estimates of lithium over 
placebo in prevention of any mood episode for studies 
assesses as being at high, moderate and low risks of bias 
were 0.58 (95 % CI 0.47–0.71), 0.60 (0.52–0.69) and 0.80 
(0.54–1.19) in the theoretically expected ascending order, 
thus validating our assessment of RoB.
Table  2 represents the contribution matrix of each 
direct comparison to network estimates. Summating 
percentage contributions from direct estimates (Table 2) 
at low, moderate or high RoB according to Table  1, we 
obtain Table 3, which shows the percentage of contribu-
tions from direct comparisons at high, moderate or low 
risks of bias to each network estimate.
For example, 0.2, 22.5 and 77.6 % of the contributions 
to the network estimate for placebo vs lithium in pre-
venting any mood episode come from direct comparisons 
with low, moderate and high, respectively, risks of bias. 
Figure 2 graphically presents the respective contributions 
for major comparisons in the network.
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Thus the network estimate of efficacy of lithium over 
placebo to prevent any mood episode was based nearly 
80  % on studies at high risk of bias and nearly 20  % on 
studies at moderate risk of bias. This estimate would 
then be considered quite likely to be biased, either in the 
direction of under- or over-estimation.
Contribution of the enrichment design to network 
estimates
Table 4 shows the percentage of enriched participants for 
each direct comparison.
Multiplying Table  4 by the contribution matrix for 
depressive episode relapse and that for mania episode 
relapse (Table  2), we obtain Table  5, which shows the 
percentage of contributions of the enrichment design to 
network estimates. For example, the NMA estimate of 
efficacy of placebo versus lithium in preventing depres-
sive episode relapses receives 12.1  % of contributions 
from studies favouring lithium, 10.5  % from studies 
favouring placebo, 0.1  % from studies with enrichment 
design whose direction could not be determined, and the 
remaining 77.3 % from non-enriched studies.
We graphically showed the percentages of contri-
butions of enriched vs non-enriched studies to effect 
estimates of main comparisons against placebo in the 
network (Fig. 3).
Thus, the network estimate of the efficacy of lithium vs 
placebo to prevent a depressive episode received a small 
contribution from studies enriched in favour of lithium, 
and a similarly small contribution from studies enriched 
in favour of placebo but the bulk of the evidence was 
from non-enriched studies. By contrast, the network 
estimates of fluoxetine or lamotrigine in the prevention 
of depressive episodes received nearly half or more con-
tribution from studies enriched in favour of the active 
drugs: it is quite possible that the network estimates for 
these drugs are overestimated.
Discussion
We have demonstrated how to appraise the impact of 
study limitations of included studies on each estimate 
obtained in the NMA according to the GRADE system 
in a transparent and quantitative manner, first in the case 
of standard risks of bias as assessed with the Cochrane 
method and then also in the case of study limitations 
Table 3 Contribution of  risks of  bias of  direct estimates 
to network estimates
Contributions of direct comparisons at high, moderate or low risk of bias to 
mixed or indirect comparisons were calculated as the sum of direct comparisons 
with corresponding risks of bias, weighted by the contribution matrix
ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, 
LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, 
PAL paliperidone, PLB placebo, QTP quetiapine, RisLAI risperidone long-acting 
injection, VPA valproate
Comparison Any mood episode relapse
Low (%) Moderate (%) High (%)
PLB vs LIT 0.2 22.5 77.6
PLB vs VPA 0.1 22.0 77.9
PLB vs LTG 0.1 8.1 91.7
PLB vs IMP 0.5 27.7 71.9
PLB vs LIT + IMP 1.0 46.2 53.1
PLB vs ARP 0.0 100.0 0.0
PLB vs OLZ 0.1 67.2 32.8
PLB vs QTP 0.1 12.0 87.9
PLB vs RisLAI 0.0 86.9 13.2
PLB vs PAL 0.0 100.0 0.0
Fig. 2 Contributions from studies at high, moderate or low risk of bias to RR to prevent any mood episodes. ARP aripiprazole, CBZ carbamazepine, 
FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, 
RisLAI risperidone long-acting injection, VPA valproate (Figure dapted from p. 98 of the Appendix in Miura et al. [4])
Page 10 of 13Furukawa et al. BMC Res Notes  (2016) 9:218 
Ta
bl
e 
4 
Pe
rc
en
ta
ge
 o
f e
nr
ic
he
d 
pa
rt
ic
ip
an
ts
 fo
r e
ac
h 
di
re
ct
 c
om
pa
ri
so
n
AR
P 
ar
ip
ip
ra
zo
le
, C
BZ
 c
ar
ba
m
az
ep
in
e,
 F
LX
 fl
uo
xe
tin
e,
 IM
P 
im
ip
ra
m
in
e,
 L
IT
 li
th
iu
m
, L
TG
 la
m
ot
rig
in
e,
 O
LZ
 o
la
nz
ap
in
e,
 O
XC
 o
xc
ar
ba
ze
pi
ne
, P
AL
 p
al
ip
er
id
on
e,
 P
LB
 p
la
ce
bo
, Q
TP
 q
ue
tia
pi
ne
, R
is
LA
I r
is
pe
rid
on
e 
lo
ng
-a
ct
in
g 
in
je
ct
io
n,
 V
PA
 v
al
pr
oa
te
D
ire
ct
 c
om
pa
ri
so
ns
PL
B 
 
vs
 L
IT
PL
B 
 
vs
 V
PA
PL
B 
 
vs
 LT
G
PL
B 
 
vs
 IM
P
PL
B 
 
vs
 F
LX
PL
B 
LI
T+
IM
P
PL
B
vs
 
A
RP
PL
B 
vs
 
O
LZ
PL
C
vs
 Q
TP
PL
B 
Ri
sL
A
I
PL
B 
vs
 
PA
L
LI
T 
vs
 
VP
A
LI
T 
 
vs
 
CB
Z
LI
T 
vs
 
LT
G
LI
T 
 
vs
 IM
P
LI
T 
 
vs
 L
X
LI
T 
vs
 
LI
T+
IM
P
LI
T
vs
 
LI
T+
VP
A
LI
T 
vs
 
LI
T+
O
XC
LI
T 
vs
 
O
LZ
LI
T 
vs
 
Q
TP
VP
A
 v
s 
LI
T+
VP
A
VP
A
 v
s 
VP
A
+A
RP
LT
G
 v
s 
VP
A
+L
TG
LT
G
 v
s 
A
RP
+L
TG
IM
P 
vs
 
LI
T+
IM
P
O
LZ
 v
s 
Ri
sL
A
l
M
an
ic
(%
)
0
0
29
0
–
0
10
0
58
42
72
10
0
0
0
26
0
–
22
0
0
0
72
0
10
0
0
10
0
41
10
0
D
ep
re
s-
si
on
 
(%
)
0
0
79
0
10
0
0
0
0
58
0
0
0
0
76
0
10
0
25
0
0
0
28
0
0
10
0
0
46
0
Page 11 of 13Furukawa et al. BMC Res Notes  (2016) 9:218 
which have clear directions and have complex repercus-
sion in the network.
The GRADE framework has been developed to provide 
a common, sensible method to assess quality of evidence 
and the strength of recommendation, and successfully 
applied to conventional pair-wise meta-analyses and 
clinical guidelines. However, it is difficult to apply the 
GRADE to NMAs mainly because of the complexity of 
NMAs. For, in NMA, risk of bias for mixed or network 
estimates are hard to evaluate, especially in a large net-
work, because mixed estimates are calculated from both 
direct and indirect estimates with different contributions.
With netweight, a command for NMA in STATA [8], 
we can obtain the contribution matrix showing contribu-
tions from each direct comparison to the network esti-
mates even in a large network like our example, and then 
we can calculate the composition of each level of risk of 
bias in network estimates quantitatively. We have demon-
strated and exemplified that this method, first presented 
by Salanti et  al. [3], is flexible enough to accommodate 
other sources of bias, including even those which have 
directions such as the enrichment design in our case.
Admittedly assessments of RoB and GRADE contain 
strong elements of judgment. Our endeavors represent 
quantification of these judgments in a reasonable and 
explicit way and represents important advance in making 
these judgments more transparent to consumers of evi-
dence (patients, clinicians and policy makers). However 
we must remember that in essence they are attempts at 
quantification of in part qualitative statements.
One important consideration when downgrading for 
study limitation is whether actually studies at high risk 
of bias give materially different results from those at low 
risk of bias. If the disagreement is significant, researcher 
might choose to base their conclusions only on stud-
ies at low risk of bias. When both sources of evidence 
are in agreement, some reviewers might be reluctant to 
downgrade for study limitations. When disagreement is 
not substantial and yet not negligible, as it is the case in 
our example, appropriate statistical methodology should 
be applied to quantify the potential impact of those high 
risk of bias studies. In order to examine if studies rated 
at high RoB do in fact differ or not differ in effect esti-
mates from those rated at low RoB, one solution might be 
to run subgroup NMA (or meta-regression) to compare 
the results among those with high RoB and those with 
low RoB. Others may argue however that, comparing 
two scenarios where, in one case, all high quality studies 
provide similar results and, in another case, half are high 
quality and half are low quality yet both provide similar 
results, the rating for the resultant meta-analytic results 
should nonetheless be higher for the former than for the 
latter. In practice, few network meta-analyses would have 
enough power to detect material differences between 
high and low risk of bias studies, so that the question 
about comparability of results between low and high risk 
of bias studies has to be answered by large-scale empiri-
cal studies [11, 12]. These studies have provided evidence 
that some risk of bias components might be important 
when the outcome is not mortality.
Table 5 Contributions from studies with enrichment design to mixed and indirect estimates
When patients were recruited in manic (or depressive) episodes and stabilised with drug A and then after stabilisation randomised to drug A vs drug B, then such 
patients were considered to have been enriched against manic (or depressive) relapses but not for depressive (or manic) relapses. Contributions of the effects from 
studies with enrichment design to mixed or indirect comparisons were calculated as the sum of the proportion of such patients in each direct comparison, weighted 
by the contribution matrix
ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, 
QTP quetiapine, RisLAI risperidone long-acting injection, VPA valproate
Depressive episode relapse Mania episode relapse
In favour of the  
drug to the  
right (%)
In disfavour  
of the drug to the  
right (%)
Enrichment 
of unknown  
direction (%)
In favour of  
the drug  
to the right (%)
In disfavour  
of the rug  
to the right (%)
Enrichment 
of unknown
direction (%)
PLB vs LIT 12.12 10.49 0.05 5.73 6.83 0.24
PLB vs VPA 5.51 0.00 4.82 3.34 0.00 4.18
PLB vs LTG 48.26 0.00 1.94 21.75 0.00 1.51
PLB vs IMP 5.80 5.20 7.43 2.97 4.76 6.03
PLB vs FLX 68.79 0.00 3.02 – – –
PLB vs LIT + IMP 17.76 0.00 5.03 13.26 0.00 3.53
PLB vs ARP 0.00 0.00 0.00 99.90 0.00 0.00
PLB vs OLZ 2.59 0.00 2.25 45.83 20.40 0.22
PLB vs QTP 40.87 0.00 2.40 33.53 0.00 1.61
PLB vs RisLAI 0.69 0.00 0.58 72.94 0.00 0.03
PLB vs PAL 0.00 0.00 0.00 100.00 0.00 0.00
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Netweight can calculate contributions of each direct 
comparison to the entire network, and therefore the 
ranking of treatments. The present paper focused on the 
evaluation of the confidence placed on pairwise treat-
ment effects estimated via NMA rather than treatment 
ranking. Although the reporting of treatments’ ranking 
has become increasingly popular and can be clinically 
useful, it is only an auxiliary output and researchers are 
warned against consideration of the ranking in isolation 
from the effect sizes. We therefore think that it is clini-
cally more meaningful and important to evaluate the 
pairwise effect sizes rather than globally assess the qual-
ity of the network evidence as a whole.
In future attempts to apply the GRADE system to 
NMAs, a systematic and quantitative approach to evalu-
ating how study limitations of individual studies con-
tribute to each network estimate is recommended and 
should also be endorsed by scientific journals across the 
field of evidence synthesis.
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